scholarly journals Association Between Serum Fibroblast Growth Factor 21 and Mortality Among Patients With Coronary Artery Disease

2016 ◽  
Vol 101 (12) ◽  
pp. 4886-4894 ◽  
Author(s):  
Qing Li ◽  
Yuan Zhang ◽  
Ding Ding ◽  
Yunou Yang ◽  
Qian Chen ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Artery Disease

scholarly journals Is serum Fibroblast Growth Factor 21 associated with the severity or presence of coronary artery disease?

2021 ◽  
Author(s):  
Gokay Nar ◽  
Sara Cetin Sanlialp ◽  
Rukiye Nar ◽  
Oguz Kilic ◽  
Mehmet Furkan Ozen ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Negative Relationship ◽  
Risk Scores ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Significant Difference ◽  
Artery Disease

Aim: Recent studies have shown that increased circulating concentrations of fibroblast growth factor 21 (FGF21) are associated with obesity, metabolic disorder, and atherosclerosis. However, the studies which investigate the relationship between serum FGF21 levels and coronary artery disease (CAD) include conflicting data. In this study, we planned to investigate the role of FGF21 in CAD development and CAD severity. Method: Seventy-eight patients with stable angina pectoris (SA) (lesion positive) and 40   control patients (lesion negative) with similar cardiovascular risk factors who underwent coronary angiography were included in the study. Serum FGF21 levels were measured by ELISA method. CAD severity was evaluated by using SYNTAX and GENSINI risk scores. Results:  Although there was a statistically significant difference between serum FGF21 levels in the SA and the control groups [101.18 ± 141.62 vs. 47.93 ± 58.74 pg/mL; p = 0.03], no correlation was found between the SYNTAX (r = 0.146 and p = 0.134) and GENSINI (r = 0.211 and p = 0.084) scores with serum FGF21 levels. The SA group had lower serum HDL-C levels (41.57 ± 11.40 vs. 54.90 ± 34.47; p = 0.02). There was a significant and negative relationship between serum FGF21 and serum HDL-C levels in correlation analysis (r = - 0.272; p = 0.026). Conclusion: The serum FGF21 levels are different between SA diagnosed and control patients. FGF21 may be a marker for CAD diagnosis, but not for the evaluation of CAD severity. To the best of our knowledge, this is the first study to evaluate coronary artery disease severity together with a lipid profile.

scholarly journals Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2

Circulation ◽  
2002 ◽  
Vol 105 (7) ◽  
pp. 788-793 ◽  
Author(s):  
Michael Simons ◽  
Brian H. Annex ◽  
Roger J. Laham ◽  
Neal Kleiman ◽  
Timothy Henry ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Pharmacological Treatment ◽  
Fibroblast Growth Factor 2 ◽  
Fibroblast Growth ◽  
Artery Disease
Sign in / Sign up

Export Citation Format

Share Document